Olanzapine (Long-Acting)
Trade name
Zyprexa Relprevv
Presentation and preparation
|
Vial size
(powder volume) |
Fluid to add
|
Volume to add
|
Resulting concentration
|
|---|---|---|---|
| 210 mg (0.1 mL) |
Diluent provided | 1.3 mL | 150 mg/mL |
| 300 mg (0.2 mL) |
Diluent provided | 1.8 mL | 150 mg/mL |
| 405 mg (0.4 mL) |
Diluent provided | 2.3 mL | 150 mg/mL |
Follow the instructions provided in the Product Information. Reconstitute to 150 mg/mL with diluent provided. Shake vigorously.
IV administration
Never administer intravenously.
Other routes of administration
IM: Suitable. Give reconstituted suspension undiluted by deep IM injection into gluteal muscle. After the insertion of needle into the muscle, aspirate to verify no blood appears. If blood is visible, discard syringe and use a different site. Do not massage injection site.
SC: Not recommended.
Additional information
Do not confuse Zyprexa Relprevv with the olanzapine short-acting preparation Zyprexa IM. Refer to Product Information for details.
Monitor patient for signs and symptoms of overdose (e.g. sedation, delirium) every 30 minutes for at least 2 hours after injection.
Concomitant use of CNS depressants (e.g. opioids, parenteral benzodiazepines) increases the risk of respiratory depression, sedation, coma and death.
Administration may cause hypotension and bradycardia.
Use only when facilities for cardiac monitoring and cardio-respiratory resuscitation exist.
May cause contact dermatitis; wear gloves during preparation.
Reconstituted suspension should be opaque and yellow.
Use provided needles to prevent blockage, or as per relevant local guideline. Needle size selection depends on age and weight. Provided needles:
Non-obese: 19 gauge (1.5 inch or 38 mm)
Obese: 19 gauge (2 inch or 50 mm)
Do not massage injection site.
Discard any unused vial contents.